# A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen

> **NCT00931463** · PHASE4 · COMPLETED · sponsor: **Kirby Institute** · enrollment: 558 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** raltegravir
- **DRUG:** 2N(t)RTI
- **DRUG:** Ritonavir-boosted lopinavir

## Key facts

- **NCT ID:** NCT00931463
- **Lead sponsor:** Kirby Institute
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2012-09
- **Final completion:** 2013-08
- **Target enrollment:** 558 (ACTUAL)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00931463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00931463, "A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00931463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*